Welcome to our dedicated page for Ucb S A news (Ticker: UCBJY), a resource for investors and traders seeking the latest updates and insights on Ucb S A stock.
The UCB SA UNSP/ADR (UCBJY) news feed on Stock Titan aggregates company disclosures and third‑party coverage related to UCB, a Brussels‑based global biopharmaceutical company. UCB’s recent press releases focus on clinical data, regulatory‑relevant milestones, manufacturing investments and collaborations that shape its outlook in immune and central nervous system diseases.
Investors and healthcare observers following UCBJY can expect frequent news about BIMZELX (bimekizumab‑bkzx), UCB’s monoclonal antibody targeting IL‑17A and IL‑17F. Recent announcements have highlighted multi‑year data in moderate‑to‑severe plaque psoriasis, hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis, with results presented at major congresses such as EADV and EULAR. These updates often describe durability of response, stringent clinical endpoints and safety profiles in Phase 3 and open‑label extension studies.
The UCBJY news stream also features updates from UCB’s epilepsy and rare disease portfolio, including data on FINTEPLA (fenfluramine) in Dravet syndrome and Lennox‑Gastaut syndrome, positive Phase 3 results in CDKL5 deficiency disorder, and research on developmental and epileptic encephalopathies. Additional releases cover work in thymidine kinase 2 deficiency, myasthenia gravis community initiatives, and broader rare disease programs.
Beyond clinical results, UCB publishes news on manufacturing and technology strategy, such as its planned U.S. biologics manufacturing facility and its collaboration with Domino Data Lab to modernize a statistical computing environment. For users tracking UCBJY, this page offers a consolidated view of how UCB reports progress across R&D, operations and patient‑focused initiatives. Bookmark this feed to review new trial readouts, congress presentations, strategic investments and patient‑community programs as they are released.
UCB has announced that the FDA has accepted its Biologic License Application (BLA) for rozanolixizumab, aimed at treating adults with generalized myasthenia gravis (gMG). The application has been designated for Priority Review, potentially expediting the regulatory process. This follows the EMA's validation of the Marketing Authorization Application for the same drug. The BLA is supported by positive results from the Phase 3 MycarinG study, which showed statistically significant improvements in patients. UCB expects agency feedback in Q2 2023.
UCB has announced positive top-line results from two Phase 3 studies, BE HEARD I and BE HEARD II, for their investigational drug bimekizumab targeting moderate to severe hidradenitis suppurativa. Both studies met primary and key secondary endpoints, indicating significant improvements over placebo. These results will support global regulatory applications beginning Q3 2023. Bimekizumab demonstrated a consistent safety profile with no new safety signals detected. The studies also suggest that targeting both IL-17A and IL-17F could provide a promising treatment approach.
UCB announced the publication of two articles in The Lancet, detailing results from Phase 3 studies BE OPTIMAL and BE COMPLETE on bimekizumab, an investigational treatment for psoriatic arthritis. Both studies met primary and secondary endpoints, with statistically significant improvements in joint symptoms and skin clearance compared to placebo (p<0.0001). Bimekizumab's safety profile remained consistent with previous data. However, it is important to note that bimekizumab has not been approved by the U.S. FDA and its safety and efficacy remain unestablished in the U.S.
UCB presented 21 scientific studies, including 7 late-breaking findings, at the 76th American Epilepsy Society (AES) Annual Meeting in Nashville, highlighting their commitment to epilepsy care. Key updates include data on the efficacy and safety of UCB's anti-seizure medications: BRIVIACT®, FINTEPLA®, VIMPAT®, and NAYZILAM®. Topics covered include real-world treatment outcomes, health equity, and cognitive effects in pediatric patients. UCB aims to advance the understanding of epilepsy, particularly in underserved populations, through ongoing research and educational initiatives.
UCB announced positive results from a Phase 3 open-label extension study of FINTEPLA (fenfluramine) for treating Lennox-Gastaut syndrome (LGS). Over a median duration of 15 months, FINTEPLA significantly reduced the frequency of various seizure types. Key findings include a 28.6% overall reduction in seizures associated with a drop, and a 50.5% reduction by month 15. Additionally, no valvular heart disease or pulmonary arterial hypertension cases were reported, reinforcing FINTEPLA's safety profile. This medication is FDA-approved for patients aged 2 and above.
UCB announced the acceptance of its New Drug Application (NDA) for zilucoplan by the U.S. FDA, intended for treating generalized myasthenia gravis (gMG) in adults who are acetylcholine receptor antibody positive (AChR-Ab+). This follows the European Medicines Agency's validation of its Marketing Authorization Application (MAA) for the same treatment. Both applications are based on the pivotal Phase 3 RAISE study, showing significant improvements in key outcomes. UCB anticipates feedback from regulatory bodies in Q4 2023.
UCB presented late-breaking 52-week data from three Phase 3 studies of bimekizumab for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) at ACR Convergence 2022. Results showed sustained clinical responses for patients treated with bimekizumab, with significant improvements in joint and skin clearance. The studies reported a consistent adverse event profile and no new safety signals. Key findings include ACR50 response at 54.5% and complete skin clearance in 60.8% of PsA patients. Bimekizumab is not FDA-approved for any indication in the U.S.
UCB is set to present 15 abstracts at ACR Convergence 2022 in Philadelphia from November 10-14, focusing on its rheumatology portfolio. Notably, the presentation includes late-breaking 52-week data for bimekizumab in treating psoriatic arthritis and axial spondyloarthritis. This data will be shared through four oral presentations and eight e-posters, underscoring UCB's dedication to advancing treatment standards. Bimekizumab is still under investigation and not yet approved by the FDA. CIMZIA® data will also be presented, highlighting its use in active axial spondyloarthritis.
UCB announces its Atlanta Warehouse as the first dually certified WELL Platinum and LEED Gold pharmaceutical project globally. This signifies UCB's commitment to sustainability and employee well-being. The building supports innovative work environments, having achieved notable sustainability metrics, including a 30% reduction in energy consumption and diverting 85% of waste during construction. UCB aims for a 35% reduction in CO2 emissions by 2030. This project underscores UCB's dedication to creating a healthier workplace and minimizing environmental impact in the Atlanta community.
UCB presented new data on its investigational treatments for generalized myasthenia gravis (gMG) at the AANEM annual meeting. Key studies included the Phase 3 MycarinG study for rozanolixizumab and the RAISE studies for zilucoplan. Rozanolixizumab showed significant efficacy in MuSK-Ab+ gMG patients, with improvements in MG-ADL scores. Zilucoplan demonstrated a favorable safety profile and ongoing efficacy in long-term studies. Both treatments are not yet approved, and UCB plans EU, Japan, and U.S. regulatory submissions later this year.